X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Divis Laboratories with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ACTAVIS (US) - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   ACTAVIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
ACTAVIS
Dec-14
DIVIS LABORATORIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,14219,494-   
Low Rs53311,891-   
Sales per share (Unadj.) Rs146.63,510.4-  
Earnings per share (Unadj.) Rs33.0-438.1-  
Cash flow per share (Unadj.) Rs38.4322.1-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs222.87,613.9-  
Shares outstanding (eoy) m265.47265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.74.5 127.8%   
Avg P/E ratio x25.3-35.8 -70.8%  
P/CF ratio (eoy) x21.848.7 44.8%  
Price / Book Value ratio x3.82.1 182.3%  
Dividend payout %30.30-   
Avg Mkt Cap Rs m222,3184,172,667 5.3%   
No. of employees `00010.821.6 49.8%   
Total wages/salary Rs m4,5610-   
Avg. sales/employee Rs Th3,616.043,213.5 8.4%   
Avg. wages/employee Rs Th423.80-   
Avg. net profit/employee Rs Th814.9-5,392.6 -15.1%   
INCOME DATA
Net Sales Rs m38,915933,411 4.2%  
Other income Rs m1,134-2,330 -48.7%   
Total revenues Rs m40,049931,081 4.3%   
Gross profit Rs m12,617119,910 10.5%  
Depreciation Rs m1,425202,117 0.7%   
Interest Rs m1329,442 0.0%   
Profit before tax Rs m12,313-113,979 -10.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,361 0.0%   
Tax Rs m3,543-5,860 -60.5%   
Profit after tax Rs m8,770-116,480 -7.5%  
Gross profit margin %32.412.8 252.4%  
Effective tax rate %28.85.1 559.7%   
Net profit margin %22.5-12.5 -180.6%  
BALANCE SHEET DATA
Current assets Rs m45,351491,788 9.2%   
Current liabilities Rs m6,507358,658 1.8%   
Net working cap to sales %99.814.3 699.8%  
Current ratio x7.01.4 508.3%  
Inventory Days Days12758 218.4%  
Debtors Days Days9566 143.5%  
Net fixed assets Rs m21,160113,979 18.6%   
Share capital Rs m5310-   
"Free" reserves Rs m58,6250-   
Net worth Rs m59,1562,024,533 2.9%   
Long term debt Rs m01,060,895 0.0%   
Total assets Rs m67,8323,710,303 1.8%  
Interest coverage x926.8-2.9 -32,277.8%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.60.3 228.0%   
Return on assets %12.9-2.3 -552.0%  
Return on equity %14.8-5.8 -257.7%  
Return on capital %20.8-3.0 -692.1%  
Exports to sales %00-   
Imports to sales %21.80-   
Net fx Rs m23,3170-   
CASH FLOW
From Operations Rs m7,759160,285 4.8%  
From Investments Rs m-4,783-383,783 1.2%  
From Financial Activity Rs m-3,142215,631 -1.5%  
Net Cashflow Rs m-166-7,868 2.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.46 Rs / USD

Compare DIVIS LABORATORIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DIVIS LABORATORIES With: PANACEA BIOTECH  IPCA LABS  ELDER PHARMA  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

US-China Trade Talks, Oil Prices, and Top Stocks in Action Today(Pre-Open)

On Tuesday, share markets in India witnessed selling pressure during closing hours and ended their trading session marginally lower after a volatile day of trading.

Related Views On News

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 19, 2019 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS